Seminars in Hematology
Volume 46, Issue 3 , Pages 259-268 , July 2009

Neutropenic Fever Syndromes in Patients Undergoing Cytotoxic Therapy for Acute Leukemia and Myelodysplastic Syndromes

  • E.J. Bow

      Affiliations

    • Corresponding Author InformationAddress correspondence to E.J. Bow, MD, Health Sciences Centre, Room GD600, 820 Sherbrook St, Winnipeg, Manitoba, Canada, R2A 1R9

References 

  1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–340
  2. Bodey GP, Rodriguez V, Chang HY, Narboni G. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer. 1978;41:1610–1622
  3. Leese B, Collin R, Clark DJ. The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics. 1994;6:233–239
  4. Elting LS, Shih YC. The economic burden of supportive care of cancer patients. Support Care Cancer. 2004;12:219–226
  5. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751
  6. Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, Kern WV, et al. Antimicrobial therapy of unexplained fever in neutropenic patients—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003;82(Suppl 2):S105–S117
  7. Bow EJ. Infectious complications in patients receiving cytotoxic therapy for acute leukemia: History, background and approaches to managment. In:  Wingard JR,  Bowden RA editor. Management of infection in oncology patients. London: Martin Dunitz; 2003;p. 71–104
  8. Buchheidt D, Bohme A, Cornely OA, Fatkenheuer G, Fuhr HG, Heussel G, et al. Diagnosis and treatment of documented infections in neutropenic patients—recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003;82(Suppl 2):S127–S132
  9. Santolaya ME, Rabagliati R, Bidart T, Paya E, Guzman AM, Morales R, et al. Consensus: Rational approach towards the patient with cancer, fever and neutropenia. Rev Chilena Infectol. 2005;22(Suppl 2):S79–S113
  10. Tamura K. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents. 2005;26(Suppl 2):S123–S127
  11. Freifeld AG, Segal BH, Baden LR, Brown AE, Caspar C, deShazzo M, et al. Prevention and treatment of cancer-related infections (National Comprehensive Cancer Network—Clinical Practice Guidelines in Oncology v2). April 9, 2007 http://www.nccn.org/professionals/physcian_gls/PDF/infections.pdf
  12. EORTC International Antimicrobial Therapy Cooperative Project Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis. 1978;137:14–29
  13. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996;14:636–643
  14. Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004;39(Suppl 1):S49–S52
  15. Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA. 1992;268:1578–1580
  16. Ciuraru NB, Braunstein R, Sulkes A, Stemmer SM. The influence of mucositis on oral thermometry: when fever may not reflect infection. Clin Infect Dis. 2008;46:1859–1863
  17. Mendes AV, Sapolnik R, Mendonca N. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr (Rio J). 2007;83:S54–S63
  18. Bodey GP. The treatment of febrile neutropenia: from the Dark Ages to the present. Support Care Cancer. 1997;5:351–357
  19. Curtin JA, Marshall BD. Use of antibiotics in cancer and leukemia. J Chronic Dis. 1962;15:713–718
  20. Schimpff SC, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061–1065
  21. Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH, et al. Origin of infection in acute nonlymphocytic leukemia (Significance of hospital acquisition of potential pathogens). Ann Intern Med. 1972;77:707–714
  22. Bow EJ. Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect. 2005;11(Suppl 5):24–29
  23. Marie JP, Vekhoff A, Pico JL, Guy H, Andremount A, Richet H, et al. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. J Antimicrobial Chemother. 1998;41(Suppl D):57–64
  24. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490–494
  25. Wisplinghoff H, Cornely OA, Moser S, Bethe U, Stutzer H, Salzberger B, et al. Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol. 2003;24:905–911
  26. Morris PG, Hassan T, McNamara M, Hassan A, Wiig R, Grogan L, et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia—a cause for concern. Support Care Cancer. 2008;16:1085–1088
  27. Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007;13:615–621
  28. Carratala J, Roson B, Fernandez-Sevilla A, Alcaide F, Gudiol F. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med. 1998;158:868–872
  29. Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61:721–728
  30. Chen CY, Tang JL, Hsueh PR, Yao M, Huang SY, Chen YC, et al. Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. J Formos Med Assoc. 2004;103:526–532
  31. Aubron C, Poirel L, Fortineau N, Nicolas P, Collet L, Nordmann P, et al. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital. Microb Drug Resist. 2005;11:254–259
  32. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic managment of the neutropenic patient. J Infect Dis. 1990;161:397–401
  33. Bow EJ, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis. 2006;43:447–459
  34. Pizzo PA. Fever in immunocompromised patients. N Engl J Med. 1999;341:893–900
  35. Cometta A, Calandra T, Gaya H, Zinner SH, De Bock R, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer (The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program). Antimicrob Agents Chemother. 1996;40:1108–1115
  36. Cometta A, Zinner S, De Bock R, Calandra T, Gaya H, Klastersky J, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer (The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer). Antimicrob Agents Chemother. 1995;39:445–452
  37. Akova M, Paesmans M, Calandra T, Viscoli C. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis. 2005;40:239–245
  38. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100:345–351
  39. Nucci M, Spector N, Bueno AP, Solza C, Perecmanis T, Bacha PC, et al. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis. 1997;24:575–579
  40. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715–719
  41. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715–719
  42. Sickles EA, Young VM, Greene WH, Wiernik PH. Pneumonia in acute leukemia. Ann Intern Med. 1973;79:528–534
  43. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26:5684–5688
  44. Peacock JE, Herrington DA, Wade JC, Lazarus HM, Reed MD, Sinclair JW, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients (A randomized, double-blind trial). Ann Intern Med. 2002;137:77–87
  45. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987
  46. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100:2026–2046
  47. Bochud P-Y, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P, et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18:25–31
  48. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201–2205
  49. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B, et al. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol. 1997;15:2254–2261
  50. Bow EJ, Meddings JB. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia. 2006;20:2087–2092
  51. Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 2003;21:1452–1458
  52. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–2598
  53. Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol. 2000;110:292–299
  54. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051
  55. Freifeld A. Guidelines for Antimicrobials in Neutropenic Cancer Patients. Presented at the 45th Annual Meeting of the Infectious Diseases Society of America, October 4–7, 2007; San Diego, CA.
  56. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer (A multicenter randomized trial. The Intercontinental Antimicrobial Study Group). Ann Intern Med. 1994;120:834–844
  57. Feld R, De Pauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol. 2000;18:3690–3698
  58. Stein RS, Kayser J, Flexner JM. Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer. 1982;50:2247–2251
  59. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101–111
  60. EORTC International Antimicrobial Therapy Project Group. Empiric antifungal therapy in febrile granulocytopenic patients (EORTC International Antimicrobial Therapy Cooperative Group). Am J Med. 1989;86:668–672
  61. Slavin MA, Szer J, Grigg AP, Roberts AW, Seymour JF, Sasadeusz J, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J. 2004;34:192–200
  62. Yoshida M, Ohno R. Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis. 2004;39(Suppl 1):S11–S14
  63. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer Suppl. 2007;5:32–42
  64. O'Hanley P, Easaw J, Rugo H, Easaw S. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med. 1989;87:605–613
  65. Bow EJ, Kilpatrick MG, Scott BA, Clinch JJ, Cheang MS. Acute myeloid leukemia in Manitoba (The consequences of standard “7 + 3” remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome). Cancer. 1994;74:52–60
  66. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis. 1995;21:361–369
  67. Bow EJ, Sutherland JA, Kilpatrick MG, Williams GJ, Clinch JJ, Shore TB, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol. 1996;14:1345–1352
  68. Bow EJ, Gallant G, Williams GJ, Woloschuk D, Shore TB, Rubinger M, et al. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide and carboplatin. Cancer. 1998;83:1344–1354
  69. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242–1250
  70. Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, et al. Prophylactic action of oral fluconazole against infection in neutropenic patients—a meta-analysis of 16 randomized, controlled trials. Cancer. 2000;89:1611–1625
  71. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer. 2002;94:3230–3246
  72. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359
  73. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia (National Institute of Allergy and Infectious Diseases Mycoses Study Group). N Engl J Med. 1999;340:764–771
  74. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225–234
  75. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–1402
  76. Schiel X, Link H, Maschmeyer G, Glass B, Cornely OA, Buchheidt D, et al. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II. Infection. 2006;34:118–126
  77. Bow EJ, Laverdière M, Rotstein C. A systematic review of the efficacy of azoles and lipid-based formulations of amphotericin B as empirical anti-fungal therapy in persistently febrile neutropenic patients despite broad-spectrum anti-bacterial therapy. [abstract 702] 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000;364
  78. Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M. Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur J Cancer. 2008;44:2192–2203
  79. Girois SB, Chapuis F, Decullier E, Revol BG. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2005;24:119–130
  80. Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19:253–259
  81. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, de Pauw TJ, Walsh BE, Segal BH, et al. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis. 2006;43:1449–1455
  82. Miceli MH, Maertens J, Buve K, Grazziutti M, Woods G, Rahman M, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer. 2007;110:112–120
  83. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81:213–227
  84. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006;42:1639–1646
  85. Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med. 1981;304:1185–1189
  86. Bow EJ, Schroeder ML, Louie TJ. Pulmonary complications in patients receiving granulocyte transfusions and amphotericin B. Can Med Assoc J. 1984;130:593–597
  87. Dana BW, Durie BG, White RF, Huestis DW. Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: absence of significant pulmonary toxicity. Blood. 1981;57:90–94
  88. Karp DD, Ervin TJ, Tuttle S, Gorgone BC, Lavin P, Yunis EJ, et al. Pulmonary complications during granulocyte transfusions: incidence and clinical features. Vox Sang. 1982;42:57–61
  89. Albelda SM, Talbot GH, Gerson SL, Miller WT, Cassileth PA. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis (Influence of bone marrow recovery in patients with acute leukemia). Am Rev Respir Dis. 1985;131:115–120
  90. Martino P, Girmenia C, Venditti M, Micozzi A, Gentile G, Raccah R, et al. Spontaneous pneumothorax complicating pulmonary mycetoma in patients with acute leukemia. Rev Infect Dis. 1990;12:611–617
  91. Pagano L, Ricci P, Nosari A, Tonso A, Buelli M, Montillo M, et al. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell'Adulto). Br J Haematol. 1995;89:500–505
  92. Todeschini G, Murari C, Bonesi R, Pizzolo G, Verlato G, Tecchio C, et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest. 1999;29:453–457
  93. Takahashi Y, Kobayashi Y, Chikayama S, Ikeda M, Kondo M. Effect of granulocyte/colony-stimulating factor on the onset of the adult respiratory distress syndrome. Acta Haematol. 1999;101:124–129
  94. Takuma T, Okada K, Uchida Y, Yamagata A, Sawae Y. Invasive pulmonary aspergillosis resulting in respiratory failure during neutrophil recovery from postchemotherapy neutropenia in three patients with acute leukaemia. J Intern Med. 2002;252:173–177
  95. Maertens J, Theunissen K, Deeren D, Meersseman W, Van EJ. Defining a case of invasive aspergillosis by serum galactomannan. Med Mycol. 2006;44(Suppl):173–178
  96. Shibuya K, Ando T, Hasegawa C, Wakayama M, Hamatani S, Hatori T, et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother. 2004;10:138–145

PII: S0037-1963(09)00057-2

doi: 10.1053/j.seminhematol.2009.03.002

Seminars in Hematology
Volume 46, Issue 3 , Pages 259-268 , July 2009

Article Tools

* Image Usage & Resolution